Grazoprevir/elbasvir combination therapy for HCV infection

Grazoprevir/elbasvir combination therapy for HCV infection

Interferon-free regimens combine different second-wave direct-acting antiviral agents (DAAs), which target the main viral proteins involved in the replication cycle of hepatitis C virus (HCV): NS3/4A protease inhibitors (simeprevir or paritaprevir boosted by ritonavir), NS5B nucleos(t)idic (sofosbuv...

Full description

Bibliographic Details
Main Authors:	Anaïs Vallet-Pichard, Stanislas Pol
Format:	Article
Language:	English
Published:	SAGE Publishing 2017-01-01
Series:	Therapeutic Advances in Gastroenterology
Online Access:	https://doi.org/10.1177/1756283X16671293

Similar Items

Elbasvir/Grazoprevir for HCV Infection in Russia: A Randomized Trial
by: Zhdanov K, et al.
Published: (2020-04-01)

Elbasvir/grazoprevir treatment in an HCV-infected peritoneal dialysis patient
by: Jin Chen, et al.
Published: (2020-01-01)

Elbasvir/grazoprevir in women with hepatitis C virus infection taking oral contraceptives or hormone replacement therapy
by: Hézode C, et al.
Published: (2019-11-01)

Elbasvir/Grazoprevir, an Alternative in Antiviral Hepatitis C Therapy in Patients under Amiodarone Treatment
by: Lina Weiss, et al.
Published: (2018-02-01)

Patient-reported outcomes in individuals with hepatitis C virus infection treated with elbasvir/grazoprevir
by: Ng X, et al.
Published: (2018-12-01)

Limited drug–drug interaction of elbasvir/grazoprevir for chronic hepatitis C
by: Chun-Jen Liu, et al.
Published: (2020-05-01)

Elbasvir/grazoprevir is effective and tolerable for the treatment of HCV GT1-infected patients: A real world multicenter observatory study in Taiwan
by: Pin-Nan Cheng, et al.
Published: (2021-08-01)

Spotlight on grazoprevir—elbasvir once-daily combination and its potential in the treatment of hepatitis C
by: Suraweera D, et al.
Published: (2016-06-01)

Meta-Analysis of Grazoprevir plus Elbasvir for Treatment of Hepatitis C Virus Genotype 1 Infection
by: Hussien Ahmed, et al.
Published: (2018-01-01)

Safety and efficacy of elbasvir/grazoprevir for the treatment of chronic hepatitis C: current evidence
by: Morikawa K, et al.
Published: (2018-09-01)

Elbasvir/Grazoprevir: A Review of the Latest Agent in the Fight against Hepatitis C
by: Allison M. Bell, et al.
Published: (2016-01-01)

Clinical effect of elbasvir/grazoprevir in treatment of chronic hepatitis C in the real world
by: LIU Fang
Published: (2020-10-01)

An integrated analysis of elbasvir/grazoprevir in Korean patients with hepatitis C virus genotype 1b infection
by: Youn Jae Lee, et al.
Published: (2019-12-01)

Effectiveness of Elbasvir/Grazoprevir in US Veterans with Chronic Hepatitis C Virus Genotype 1b Infection
by: Amy Puenpatom, et al.
Published: (2020-04-01)

Grazoprevir/elbasvir for the treatment of adults with chronic hepatitis C: a short review on the clinical evidence and place in therapy
by: Sulejmani N, et al.
Published: (2018-05-01)

Grazoprevir and Elbasvir in Patients with Genotype 1 Hepatitis C Virus Infection: A Comprehensive Efficacy and Safety Analysis
by: Yinan Yao, et al.
Published: (2017-01-01)

Treatment With Grazoprevir/Elbasvir for Renal Transplant Recipients With Chronic Hepatitis C Virus Infection and Impaired Allograft Function
by: Ute Eisenberger, MD, et al.
Published: (2019-01-01)

P64 Concomitant proton pump inhibitor use does not reduce the efficacy of elbasvir/grazoprevir
by: N. Reau, et al.
Published: (2017-08-01)

Preemptive Treatment With Elbasvir and Grazoprevir for Hepatitis C–Viremic Donor to Uninfected Recipient Kidney Transplantation
by: Meghan E. Sise, et al.
Published: (2020-04-01)

Effectiveness and safety of elbasvir/grazoprevir in Korean patients with hepatitis C virus infection: a nationwide real-world study
by: Eun Sun Jang, et al.
Published: (2021-03-01)

O21 HCV reinfection and injecting risk behaviour following elbasvir/grazoprevir treatment in patients on opioid agonist therapy: Co-STAR three year follow-up study
by: G. Dore, et al.
Published: (2017-08-01)

Grazoprevir/elbasvir in peginterferon alfa plus ribavirin experienced patients with chronic genotype 1 HCV/HIV co-infection: a non-randomized, open-label clinical trial
by: Lin YC, et al.
Published: (2019-04-01)

Efficacy of elbasvir/grazoprevir in treatment of genotype 1 chronic hepatitis C: A real-world study
by: XIA Yang
Published: (2020-12-01)

A Single- and Multiple-Dose Study to Evaluate the Pharmacokinetics of Fixed-Dose Grazoprevir/Elbasvir in Healthy Chinese Participants
by: Li H, et al.
Published: (2020-02-01)

Projected impact of elbasvir/grazoprevir in patients with hepatitis C virus genotype 1 and chronic kidney disease in Vietnam
by: Chizoba Nwankwo, et al.
Published: (2019-07-01)

Efficacy and Safety of Elbasvir/Grazoprevir in Hepatitis C Virus GT1- and GT4-Infected People Aged 65 Years or Older
by: Steven Flamm MD, et al.
Published: (2019-01-01)

Cost-effectiveness analysis of elbasvir-grazoprevir regimen for treating hepatitis C virus genotype 1 infection in stage 4-5 chronic kidney disease patients in France.
by: Franck Maunoury, et al.
Published: (2018-01-01)

A Retrospective Cohort Study: Safety and Effectiveness of Elbasvir/Grazoprevir ± Ribavirin Compared With Ombitasvir/Paritaprevir/Ritonavir/Dasabuvir ± Ribavirin in Patients With Chronic Hepatitis C Genotype 1 Infection
by: Hsuan-Yu Hung, et al.
Published: (2021-09-01)

Elbasvir and grazoprevir for hepatitis C virus genotype 1 infection in people with recent injecting drug use (DARLO‐C): An open‐label, single‐arm, phase 4, multicentre trial
by: Jason Grebely, et al.
Published: (2020-06-01)

Daclatasvir–sofosbuvir combination therapy with or without ribavirin for hepatitis C virus infection: from the clinical trials to real life
by: Pol S, et al.
Published: (2016-03-01)

A Hepatitis C Virus-Associated Chronic Hepatitis Patient Developing Various Adverse Events Including Severe Gingivitis, Gingival Bleeding, and Inflammation of Genital Vulva during the Course of Antiviral Therapy with Elbasvir/Grazoprevir
by: Kazuo Tarao, et al.
Published: (2017-11-01)

HCV: is mission accomplished? The pros
by: Stanislas Pol
Published: (2016-05-01)

Repurposing potential of posaconazole and grazoprevir as inhibitors of SARS-CoV-2 helicase
by: Syed Hani Abidi, et al.
Published: (2021-05-01)

Hepatitis C (HCV) therapy for HCV mono-infected and HIV-HCV co-infected individuals living in Nepal.
by: Sudhamshu Kc, et al.
Published: (2020-12-01)

Interferon-λ in HCV Infection and Therapy
by: Michael D. Robek, et al.
Published: (2010-08-01)

Sofosbuvir in therapy of chronic HCV-infection
by: C. S. Pavlov, et al.
Published: (2016-12-01)

The Predictive Factors for Favorable Outcomes of Peginterferon and Ribavirin Combination Therapy in HCV-Infected Patients
by: Javad Moayedi, et al.
Published: (2020-08-01)

The Liver Meeting 2014: Summary of Presentations on Genotype 3 HCV Infection from the 65th Annual Liver Meeting of the American Association for the Study of Liver Diseases (AASLD), Held in Boston, MA, USA, on 7th-11th November, 2014
by: Markus Peck, et al.
Published: (2015-01-01)

HCV kinetic and modeling analyses project shorter durations to cure under combined therapy with daclatasvir and asunaprevir in chronic HCV-infected patients.
by: Laetitia Canini, et al.
Published: (2017-01-01)

Antiviral therapy in HCV-infected decompensated cirrhotics
by: Danish Fazal, et al.
Published: (2010-01-01)